Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + dexamethasone + ifosfamide + cisplatin + etoposide + rituximab
- Development stage
- Unknown
- Lead developer
- University of Miami
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
VIPER is a combination chemotherapy regimen primarily investigated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The regimen incorporates the proteasome inhibitor bortezomib (Velcade) and the anti-CD20 monoclonal antibody rituximab into the DICE backbone, which consists of dexamethasone, ifosfamide, cisplatin, and etoposide. By combining targeted biological therapy with intensive multi-agent chemotherapy, the VIPER regimen aims to overcome drug resistance in aggressive non-Hodgkin lymphomas. Clinical trials have evaluated its efficacy in achieving complete and partial response rates and its ability to facilitate subsequent autologous stem cell transplantation in patients with chemo-resistant disease.
- Other names
- V-DICE-RVelcade-DICE-Rituximab
02
Targets
CD20 (B-lymphocyte antigen CD20)GR (Glucocorticoid receptor)26S proteasomeTOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on bortezomib + dexamethasone + ifosfamide + cisplatin + etoposide + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + dexamethasone + ifosfamide + cisplatin + etoposide + rituximab.